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Abstract
Background: Epidemiology of HCV infection among drug users (DUs) has been widely studied. Prevalence and
sociobehavioural data among DUs are therefore available in most countries but no study has taken into account in the
sampling weights one important aspect of the way of life of DUs, namely that they can use one or more specialized
services during the study period. In 2004–2005, we conducted a national seroepidemiologic survey of DUs, based on a
random sampling design using the Generalised Weight Share Method (GWSM) and on blood testing.
Methods: A cross-sectional multicenter survey was done among DUs having injected or snorted drugs at least once in
their life. We conducted a two stage random survey of DUs selected to represent the diversity of drug use. The fact that
DUs can use more than one structure during the study period has an impact on their inclusion probabilities. To calculate
a correct sampling weight, we used the GWSM. A sociobehavioral questionnaire was administered by interviewers.
Selected DUs were asked to self-collect a fingerprick blood sample on blotting paper.
Results: Of all DUs selected, 1462 (75%) accepted to participate. HCV seroprevalence was 59.8% [95% CI: 50.7–68.3].
Of DUs under 30 years, 28% were HCV seropositive. Of HCV-infected DUs, 27% were unaware of their status. In the
month prior to interview, 13% of DUs shared a syringe, 38% other injection parapharnelia and 81% shared a crack pipe.
In multivariate analysis, factors independently associated with HCV seropositivity were age over 30, HIV seropositivity,
having ever injected drugs, opiate substitution treatment (OST), crack use, and precarious housing.
Conclusion: This is the first time that blood testing combined to GWSM is applied to a DUs population, which improve
the estimate of HCV prevalence. HCV seroprevalence is high, indeed by the youngest DUs. And a large proportion of
DUs are not aware of their status. Our multivariate analysis identifies risk factors such as crack consumption and unstable
housing.
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Background
Drug users (DUs) are at high risk for HIV and HCV infec-
tions [1]. Among DUs, HCV, like HIV, is mainly transmit-
ted through needle sharing. However, HCV (Hepatitis C
Virus) is more easily transmitted than HIV because its
prevalence is greater than for HIV (Human Immunode-
fiency Virus), it is more resistant to desiccation [2,3] and
is also linked to the sharing of drug paraphernalia (water,
filter, spoon) [4-8]. HCV infection can, therefore, occur
after much less injection and sharing episodes [9-12]. To
minimize the risk of HIV and HCV, harm reduction poli-
cies have been adopted in many industrialized countries
[13-17]. Many studies have studied the epidemiology and
risk factors for HCV infection among DUs [18-27] and
shown that harm reduction policies have had a major
impact on HIV among DUs but a much more limited
impact on HCV infection [10,28-36]. HCV prevalence
estimates remain high [37], over 50% in the majority of
countries where data are available [38]. In all these stud-
ies, prevalence and sociobehavioural data among DUs are
available and useful for public health issues. So far, no
study has taken into account in the sampling weights one
important aspect of the way of life of DUs, namely that
they can use one or more specialized services during the
study period. This has an impact on their inclusion prob-
abilities, and accordingly on estimates.
In France, most data on HIV and HCV infection among
DUs come from notifications or highly selected popula-
tion samples [39-42] and no prevalence estimates of HIV
and HCV infection based on laboratory confirmation
were available among DUs. In 2004–2005, we therefore
conducted a national survey among DUs who resided in
metropolitan France (the ANRS-Coquelicot study) to
assess the prevalence of HIV and HCV infections based on
serum testing, the frequencies of at risk practices, and the
risk factors for HCV prevalence. To improve the estimate
of HIV and HCV prevalences, we used a sampling design
including the Generalised Weight Share Method (GWSM)
described by Ardilly and Lavallee [43,44], taking into
account the use of specialized services by each DU during
the study period.
Methods
In 2004–2005, we conducted a two stage random survey
of DUs in five French large cities (Lille, Strasbourg, Paris,
Bordeaux and Marseilles). Given the expected size of the
sample, these five cities were chosen due to the important
number of specialized structures for DUs, and the preva-
lence of drug use in each city. Prevalence rates of drug
addiction were estimated from available data on opiate
substitution treatments (OST) [31]. The five cities from
five different regions were also selected to represent the
diversity of drug addiction (products and modes of con-
sumption) in France. The first stage of the design was con-
stituted of high-and low-threshold care structures for DUs
and of general practitioners (GPs) and the second stage by
DUs. A DU to be included in the survey was a person >18
years who had injected or snorted drugs "at least once in
its life" and accepted to participate in the survey after
informed consent.
Sampling
The sampling of individuals is similar to the time-location
sampling [45]. In each city we did an exhaustive inventory
of all structures that provide services to DUs: accommoda-
tion services including residential centers, hotel rooms,
"sleep-in"; drug treatment centers including methadone
maintenance or psychotherapy; low threshold services
including needle exchange programs and outreach work
teams. We then constructed a sampling frame by half-day
that structures were open. Pairs (structure/half-day) were
selected using an unequal probability sampling. Inclusion
probabilities were proportional to the structure's active
DUs list to obtain a calendar of half-day visits of structures
for DUs selection, inclusion and data collection. In each
structure/half day visit, DUs present were selected using a
simple random sampling, except for residential centers
where all users were included. For GPs we first constituted
a random sample of GPs stratified by the volume of sub-
stitution treatment prescribed (high versus moderate).
Then, inclusion was proposed to all the DUs followed by
the selected GPs.
Subject inclusion and data collection
During each structure/half day visit, a number of DUs cor-
responding to the calculated sample size were asked to
participate and included if they consented to the interview
and self fingerprick blood sampling on dried blood spots
for HIV and HCV testing. The questionnaire was adminis-
tered over 30 to 40 minutes by professional interviewers
independent of the recruitment structures.
Interviewers had been trained for DUs interview in order
to minimize the social desirability bias with respect to
drug consumption and at risk practices. The questionnaire
explored DU'socio-demographic situation, health status,
access to HCV screening, knowledge of HCV transmission
modes, drug use, and at risk practices. Socio-demographic
variables were related to the situation at the time of the
study, such as for the level of education, employment,
houselhold and living conditions, marital status. Other
items investigated different period of DUs' lives such as
ever previous jail experience, living with their families or
not during adolescence. Health related items included
knowledge of current HIV and HCV serological status,
medical treatments, circumstances of last HCV or HIV
testing and access to HCV treatments. Perception of health
status and main health problems were investigated for the
6 months prior to interview. Drug consumed, modes ofBMC Infectious Diseases 2009, 9:113 http://www.biomedcentral.com/1471-2334/9/113
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consumption (injecting, sniffing, smoking) and at-risk
practices (sharing syringes, other injection materials,
sniffing material or glass pipes) were recorded for the last
month using the Injecting Risk Questionnaire (IRQ) [46].
DUs were also questioned on their injection and sniffing
history over their whole lives. We also collected informa-
tion on knowledge of HIV, HCV and HBV transmission
modes.
Laboratory methods
To obtain seroprevalence data, we analyzed blood sam-
ples on blotting papers. The dried blood spots (DBS) were
cut out with a punch to obtain a circle of about 6 mm
diameter, which was placed in 250 μl of 0.01 M phos-
phate sodium buffer containing 10% bovine serum albu-
min and 0.05% Tween 20 (PBS-BSA-TW) then incubated
at room temperature for one hour in an ultrasonic cleaner.
The eluted serum samples were directly used to fill the
wells of ELISA microplates (200 μL per well). The above
steps were performed strictly as recommended by the
manufacturer. The third-generation ELISA kit from Ortho-
Clinical Diagnostics (HCV 3.0, Raritan, NJ) was used to
detect anti-HCV antibodies. The same procedure was used
to detect HIV antibodies using the Ortho HIV1/2 Ab cap-
ture Elisa kit. Any anti-HIV positive sample was confirmed
by serotyping and/or western blot [47].
We assessed the validity of the ELISA technique applied to
DBS by comparing absorbance values for various serum
samples positive for anti-HCV antibodies or anti-HIV
antibodies, either tested directly as serum and as DBS elu-
ates. The data showed an excellent concordance of results
except for weakly positive sera from patients with resolved
HCV for whom HCV-antibodies could be missed. Thus
prevalence rates of HCV infection based on the DBS
method must be considered as minimal estimates (see
appendix - Additional file 1).
Ethical considerations
Blood samples were collected, after informed consent, by
means of fingerprick self-sampling. The individuals were
informed that they would not receive the results of the
tests made from fingerprick blood sampled on DBS. How-
ever, they were informed on the benefits and places of
HCV and HIV screening and treatment through leaflets
and posters in the survey participating structures. In addi-
tion during interviews, interviewers stressed the benefit of
screening and directed DUs to near by screening services.
The study protocol was approved by an ethical review
board (Autorisation Number CCPPRB 02-002) because of
its public health added value and the indirect individual
benefit for participating DUs.
Data analysis
For this kind of cross-sectional design, we classically
assign a sampling weight to each individual to estimate
the epidemiological indicators of interest (prevalence,
odds ratio etc.) in the target population. The sampling
weight is the inverse of the inclusion probability of a DU
in the survey sample. The fact that DUs can use more than
one structure during the study period has an impact on
these inclusion probabilities. To calculate a correct sam-
pling weight, we have to take into account the number of
visits in participating structures during the course of the
survey for each DU. We are in the general framework of an
indirect sampling [44] in which there are two popula-
tions: the DU, noted UA and the structures, noted UB, that
are related to one another. We want to produce an esti-
mate for UB using the existing links between the two pop-
ulations. To estimate an epidemiological indicator in a
target population UB using a sample selected from another
population UA is a major challenge if the links between
the units of the two populations are not one-to-one
because it becomes difficult to calculate the inclusion
probabilities and consequently the sampling weights. A
solution proposed by Ardilly and Lavallee is the general-
ised weight share method (GWSM) [43,44].
This technique is meant to be a methodological frame-
work to estimate weights, including several weighting
techniques used for different designs (longitudinal stud-
ies, network sampling, time-location sampling, snowball
sampling, etc...). Time-location sampling is more widely
described and used in the literature, particularly for sam-
pling hard-to-reach or hidden population [45]. However,
we introduce the GWSM as we assert that it is more appro-
priate than the time-location sampling because (1) the
GWSM is more rigorous from a sampling theoretical point
of view, while the TLS focuses on the probability of indi-
viduals' behaviour (model-based approach) and (2) the
GWSM can account for several cases where the relation-
ship between the sampling frame(s) and the target popu-
lation is more complex.
To our knowledge, this method has not been yet intro-
duced in epidemiology as a rigorous statistical method
allowing to (1) calculate sampling weights and (2)
encompass several methods more widely used and
described in the literature.
This method produces a new weight for each unit in the
target population UB which is an average of the sampling
weights of the population UA from which the sample is
selected. A fictitious sampling example is illustrated in
Figure 1. The population UA contains 16 structures and
the population UB contains 11 DUs. The shaded structures
were sampled pointing to sampled DUs. The arrows indi-BMC Infectious Diseases 2009, 9:113 http://www.biomedcentral.com/1471-2334/9/113
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cate the links between the services and the DUs. Individ-
ual 1 reported a unique visit during the survey period.
Individual 4 reported three visits in a sampled drug treat-
ment center and in two non sampled services (accommo-
dation n°13 and outreach work team n°16) represented
by the dotted arrows. Individual 8 represents a fictitious
situation in our study as it was almost impossible that a
DU was interviewed several times. In practice, three ques-
tions were asked to DUs on the number of visits and the
identification of structures visited to identify the links
between the two populations. The GWSM needs inclusion
probabilities   only for the selected units j in the sam-
ple sA. This is a major advantage in comparison with other
methods based on exact calculation of selection probabil-
ities of surveyed units. The classical sampling weights wi =
1/πi are first calculated for each individual i. Then the
number of services visited by the individual i during the
survey, noted ri and the number of times when the indi-
vidual i has visited the service k during the survey, noted
rik were calculated. Finally a new weight is calculated by
π j
A
Observed links (arrows) and declared links (dotted arrows) between the population of services and the population of drug  users, ANRS-Coquelicot study, France 2004–2005 Figure 1
Observed links (arrows) and declared links (dotted arrows) between the population of services and the popula-
tion of drug users, ANRS-Coquelicot study, France 2004–2005. The shaded boxes represent the sampled services and 
the sampled individuals.
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. For the illustrative example in figure
1, the new weights are  ,  ,
.
All results reported in this article are estimates that take
into account the two stage survey design including the
GWSM. Statistical analyses were done with Stata 9 soft-
ware. Comparisons of proportion were made with the chi-
square test, with a significance threshold of 0.05. Preva-
lence ratio (PR) and their 95% confidence intervals (CI)
were calculated to analyse univariate association between
HCV status and risk factors. A multivariate logistic regres-
sion model was then used to identify independent risk
factors for HCV seropositivity using a manual stepwise
strategy. We also tested interactions between explanatory
variables and no interaction was significant. Prevalence
odds ratios are presented in our multivariate analysis, as it
is more difficult to estimate prevalence ratios in a multi-
variate analysis taking into account the sampling design.
Results
Among the 2389 DUs who were invited to participate in
the survey, 483 refused, 444 did not correspond to the
population of interest and 1462 accepted. The participa-
tion rate was 75%. There was no significant difference
between those who participated and those who did not
for age, gender and by type of services. Reasons of refusals
included lack of time to respond (65%), psychological or
physical status judged not compatible with the comple-
tion of a questionnaire (13%), lack of interest for the
study (8.5%), refusal without reason (7.8%), 4.6% of
refusals were not documented and only 3 refusals were
linked to a care structures' staff.
Among DUs who participated, 79% accepted to provide a
fingerprick blood sample. Reasons for not providing a
blood sample were obtained on a sub sample of 53 refus-
als and included: lack of a confined space for collecting
blood or no microlancet available (24.5%), thickness of
finger skin (18.9%), refusal to self use the microlancet
(20.8%), no time (13.2%), psychological or physical sta-
tus judged not compatible with the test (11.3%) and reli-
gious reasons (3.8%). Only 3.8% persons refused by fears
to be identified and 3.8% of refusals were linked to the
non restitution of the test result. In multivariate analysis,
the main factors associated to refusal of blood sampling
were no prior HIV and HCV testing, knowing HCV trans-
mission routes and having been recruited outside a gen-
eral medical practice.
Sociodemographic characteristics
Three-quarters of DUs were males. Mean age was 35.6
years for males and 34.5 years for females. Two-thirds of
participants were unemployed. Only 45% of respondents
had a stable household. The remaining 55% did not have
their own home or did not live with a partner or their par-
ents. Among these, 19% lived in a squat or in the street.
About two thirds (61%) reported having been incarcer-
ated at least once.
HIV and HCV seroprevalence
The overall HIV and HCV seroprevalence were 10.8%
[95% CI: 6.8–16.6] and 59.8% [95% CI: 50.7–68.3],
respectively. Almost all HIV-seropositive DUs were also
infected by HCV (HIV/HCV dual infection rate = 10.2%
[95% CI: 6.3–15.9]). The HIV seroprevalence did not dif-
fer whether DU had ever injected drugs or not but
increased gradually with age with only 0.3% of DU
infected before the age of 30 years (figure 2) and differs
among the five cities from 1% in Lille to 31,5% in Mar-
seilles. There was no significant difference for HIV and
HCV seroprevalence between males and females.
HCV seroprevalence did not differ significantly among the
five cities included. Participants who had injected a drug
at least once were more than 2.5 times more often serop-
ositive for HCV (73.8%) than those who did not (27.9%).
The proportion of HCV infection was 28% among those
under 30 years of age and increased strongly after and was
maximum over 40 years (71%, Figure 2). Analysis by five-
year birth cohort (Table 1) indicates that HIV seropreva-
lence decreases in cohorts born after 1970 (less than 34
years old at the time of the survey), corresponding to DUs
who could benefit from harm reduction services fully
made available in France in 1994 (Syringe Exchange Pro-
grammes [SEP] and substitutive replacement therapy). For
HCV, seroprevalence remained high in two 5-year birth
cohorts born after 1970 and decreased for those born in
1980 and after (aged at least 24 years at the time of the
survey).
HCV screening, awareness of HCV status and HBV 
vaccination
More than 95% of respondents said they had already been
tested at least once for HIV and 91% for HCV. While the
lifetime HCV screening rate was high, the last negative test
had been done 18 months previously on average. Moreo-
ver, 27% of DUs stated they were HCV-seronegative but
they were HCV-seropositive according to biological tests.
By comparison, only 2% of DUs wrongly said they were
seronegative for HIV.
Vaccination coverage against HBV was 43% among DUs.
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Products consumed and at risk practices
In the month prior to interview, illicit psychoactive prod-
ucts consumed (whathever the mode of use) were crack/
free base (30%), cocaine (27%), heroin (20%), and
ecstasy (12%). Benzodiazepines had been consumed by
40% of respondents, hypnotics by 20% and ampheta-
mines by 7%. In the previous six months, most respond-
ents (71%) had received OST (Subutex® in 57% of cases,
methadone in 36%).
Ninety eight per cent of DUs said they had ever snorted
drugs and 70% to have ever injected drugs. Mean age at
first injection was 20.4 years with first injection done by
another DU for 83%. In the last month, 40% of DUs
reported they had injected at least once and among them
13% had shared a syringe (corresponding to 4% of all
DUs), 38% other injection materials (filter, spoon, water,
11% of DUs) and 74% had reused their own syringe (21%
of DUs). Crack users reported sharing often crack pipes
(81% during the last month).
Factors associated with HCV seropositivity
The complete list of significant variables in univariate
analysis is presented in table 2. The following variables are
only significant in the univariate analysis: HCV seroposi-
tivity was associated with having ever been jailed (preva-
lence ratio [PR] = 1.38), having a sexual partner drug user
(PR = 1.30), subjective poor health (PR = 1.40), and fear
of treatment for hepatitis C (PR = 1.33). Methadone use
(PR = 1.34), morphine sulfates use (PR = 1.38) and having
shared injection materials (PR = 1.54) in the last month
were also risk factors for HCV in univariate analysis, while
heroin use in the last month (PR = 0.59) and living in cou-
ple (PR = 0.73) were negatively associated with HCV. In
multivariate analysis (table 3), factors that remained inde-
HIV and HCV seroprevalence by age among French DUs, ANRS-Coquelicot study, France 2004–2005 (N = 817, DUs who  consented to be tested) Figure 2
HIV and HCV seroprevalence by age among French DUs, ANRS-Coquelicot study, France 2004–2005 (N = 
817, DUs who consented to be tested).
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Table 1: Seroprevalence for HIV and HCV among French DUs by 
5-year birth cohort
Year of birth % HIV+ [95% CI] % HCV+ [95%CI]
<1959 17.3 [8.6–31.9] 65.9 [43.9–82.7]
1960–1964 16.4 [8.5–29.1] 72.1 [56.1–83.9]
1965–1969 16.7 [10.4–25.8] 64.5 [53.9–73.7]
1970–1974 8.2 [1.7–31.1] 66.2 [46.8–81.3]
1975–1979 0.0 35.1 [20.3–53.5]
1980–1984 1.1 [0.2–5.9] 11.1 [4.4–25.1]
1985–1989 0.0 0.0
* ANRS-Coquelicot study 2004–2005 (N = 817 DUs who consented 
to be tested)BMC Infectious Diseases 2009, 9:113 http://www.biomedcentral.com/1471-2334/9/113
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Table 2: HCV prevalence by risk factors among French DUs*
Prevalence of HCV Prevalence Ratio 95% Confidence Interval Missing data
Age <30 years
≥ 30 years 67.45 2.43 2.04–3.60 4
Situation Single 64.96
In couple 47.38 0.73 0.72–0.74 3
Type of household Stable 50.90
Precarious 67.42 1.32 1.32–1.33 16
Ever been jailed No 48.00
Yes 66.11 1.38 1.37–1.39 0
Percieved health (last 6 months) Good 52.02
Bad 72.98 1.40 1.39–1.41 0
HIV serology Negative 55.69
Positive 94.12 1.69 1.68–1.70 0
Fear of HCV Treatment No 50.26
Yes 66.86 1.33 1.32–1.34 2
Injected at least once No 27.90
Yes 73.82 2.65 2.58–2.71 0
Shared injection materials in the last month No 55.96
Yes 86.17 1.54 1.53–1.55 2
Sexual partner drug user injector (last 6 months) No 56.38
Yes 73.30 1.30 1.29–1.31 0
Heroine (last month) No 64.76
Yes 38.11 0.59 0.57–0.60 0
Methadone (last month) No 54.17
Yes 72.82 1.34 1.34–1.35 0
Moscontin (last month) No 57.21
Yes 78.69 1.38 1.36–1.39 0
Crack (last month) No 53.75
Yes 71.51 1.33 1.32–1.34 0
Substitution therapy (last 6 months) No 31.77
Yes 67.75 2.13 2.07–2.20 0
* ANRS-Coquelicot study, France, 2004–2005 (N = 817 DUs who consented to be tested)
Table 3: Independent risk factors for HCV seropositivity*
Variable Adjusted OR** 95% Confidence Interval
Age
<30 ans 1.00
≥ 30 ans 3.44 1.46–8.12
Type of housing
Stable 1.00
Precarious 1.80 0.99–3.27
HIV serology
Negative 1.00
Positive 29.17 9.79–86.87
Injected at least once
No 1.00
Yes 9.25 4.02–21.27
Crack smoking (last month)
No 1.00
Yes 2.65 1.19–5.91
Substitution therapy
No 1.00
Yes 3.24 1.01–10.37
* Multiple logistic regression analysis among French DUs. ANRS-Coquelicot study, France, 2004–2005 (N = 794)
**The reported prevalence odds ratios were adjusted for all the characteristics included in the table.BMC Infectious Diseases 2009, 9:113 http://www.biomedcentral.com/1471-2334/9/113
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pendently associated with HCV seropositivity were age
over 30 (prevalence odds ratio [OR] = 3.4), HIV seroposi-
tivity (OR = 29.2), having ever injected drugs (OR = 9.2),
OST in the last 6 months (OR = 3.2), crack smoking in the
last month (OR = 2.7), and precarious housing (OR =
1.8).
The multivariable analysis stratified by gender indicated
some differences by gender. HCV seropositivity was asso-
ciated with being HIV-positive (OR = 22.3), having ever
injected drugs (OR = 10.4), being unemployed (OR =
3.5), history of abscesses in the last 6 months (OR = 4.8),
having snorted drug in the last month (OR = 7.2), ever use
of hypnotic drugs (OR = 0.1) or use of cannabis in the last
month (OR = 0.3) among females. For males significant
factors were having ever injected drugs (OR = 15,7), age
over 30 years (OR = 9.6), no regular income (OR = 3),
knowledge of HIV transmission modes (OR = 6.7), report
of oedema of hands and feet in the last 6 months (OR =
3.4), use of methadone in the last month (OR = 2.3) and
having smoked drugs in the last month (OR = 2.5), going
to drug treatment centre the day before the study (OR =
0.4), prior HIV test (OR = 0.4) and consumption of heroin
in the last month (OR = 0.4).
Discussion
To our knowledge this is the first national survey among
DUs, enabling estimates of HIV and HCV prevalence rates
and their confidence intervals, based on a random sam-
pling design using the Generalised Weight Share Method
(GWSM) and blood testing. It is also the first attempt to
apply the GWSM to a public health study. This method
was previously used in a demographic survey of French
homeless people [43] whose relationships with support
facilities are almost similar to those of DUs. Our random
sampling design allowed us to make inference to the
French DUs reached by specialized services and GPs, and
to obtain correct confidence intervals.
The use of GWSM with blood testing is a way to obtain
more valid estimates of HCV prevalence. We showed that
27% of DUs were not aware of their HCV-seropositive sta-
tus, probably because they had become infected since
their last test. Therefore, HCV prevalence estimates based
on declarative data do not reflect the real prevalence
among DUs.
Because our study targeted DUs managed in specialized
centers and by GPs, it does not provide information on
"hidden" populations of DUs that do not use such serv-
ices [48,49]. Furthermore, without available precise cen-
sus data on the French DUs population, no post
stratification could be done. In our study, the youngest,
the most socially inserted and the females DUs are less
likely to use DUs specialized structures which may have
biased our estimates. However, better socially inserted
DUs were partly included in the study through recruit-
ment by GPs. A declaration bias by structures of the size of
the population of DUs they care for is possible to increase
public funding and could impact the sampling design.
However, nothing allows us to assert that certain struc-
tures had overestimated DUs' visits more than others. We
made an important effort to limit such biases by securing
a high confidentiality of data collection and recording. A
desirability bias is also possible as in all studies of stigma-
tized behaviours. To limit its impact we used professional
interviewers who were totally independent of the investi-
gated structures. Interviewers were trained and followed
up during field data collection through meetings to main-
tain homogeneity, create a reliable climate towards DUs
and to limit the social desirability bias. Although cities
were not chosen at random, structures were included in 5
cities all over France to reflect the diversity of drug use in
France and visit days in the structures and DUs were ran-
domly selected. There were no differences by sex, age and
service between participants and those who refused partic-
ipation, however, no other data was available for compar-
ison and guarantee comparability of those who refused
and participated.
Despite these limitations, we believe that using this inno-
vative statistical approach has improved the efficiency of
our study and gave more valid estimates of the HIV and
HCV public health burden among DUs and associated
risk factors.
In the ANRS-Coquelicot study, the HCV seroprevalence
(59.8%) is more than five times greater than for HIV
(10.8%) and almost all those infected by HIV were also
infected with HCV which stresses the huge public health
burden of both infections in this population. HCV sero-
prevalence did not differ significantly among the five cit-
ies included, although HIV prevalence differed
significantly between Lille (1%) and Marseilles (31.5%).
This finding is probably related to differences in at-risk
behaviour by city: in Marseille DUs are known to inject
more (83% had ever injected) than DUs from other cities
(65%). In the years 1970s to 1990s, DUs from south of
France (including Marseille) injected heroin much more
than in the North of France (including Lille) where heroin
was more often smoked which is at much lower risk of
HIV transmission.
Our analysis by year of birth indicates that the French
harm reduction policy, fully implemented since 1994
(SEP and OST), had probably a strong impact on HIV
transmission but much less and delayed for HCV trans-
mission. We recognize that one must be careful when
establishing a link between harm reduction programmes
and their differentiated impact on HIV and HCV using aBMC Infectious Diseases 2009, 9:113 http://www.biomedcentral.com/1471-2334/9/113
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cross-sectional study. However, in France and in other
western countries, the decrease of HIV prevalence among
DUs, although partially explained by mortality, and the
small proportion of DUs among HIV patients who
recently discovered their HIV status observed since the
implementation of harm reduction policies strongly sug-
gest a link with harm reduction programmes [10,28-36].
The high HCV seroprevalence among DUs with about
30% of those under 30 years of age affected is a finding of
high public health concern. It results from a combination
of several factors, including the high prevalence of HCV
infection (59.8%) in the global population, the higher
transmissibility of HCV compared to HIV, and difficulties
for DUs to reduce further behaviors at risk of HCV infec-
tion [50]. In addition to syringe and needles sharing, HCV
is also transmitted by sharing drug paraphernalia (water,
spoon, filter...) [4,7,8]. In our study the level of drug par-
aphernalia sharing (38%) remains substantial, and
syringe reuse (74%) is very high. Reuse of a personal
syringe can also be risky for HCV transmission if the drug
solution is drawn from a shared container and can be con-
sidered as an "indirect sharing". The high HCV seropreva-
lence before 30 years old indicates that DUs are rapidly
infected after drug initiation. New and young DUs are
often initiated by older peers (83% in our study) who,
because they are older, are more likely to be infected with
HCV [51,52]. Furthermore, a third of DUs (27%) are not
aware of their HCV seropositive status. HCV infection
often occurs early after adoption of the intravenous route
[9,12,53-55]. Therefore, the opportunity of HCV trans-
mission will remain substantial without implementing
new prevention strategies that target all these critical
points.
Our multivariate analysis confirmed known risk factors
for HCV infection, such as age, injection at least once and
HIV seropositivity [23,56,57]. We also identified crack
consumption and unstable housing conditions as risk fac-
tors. Social vulnerability and precarious housing condi-
tions expose DUs to a greater risk of HCV transmission
because they are dependent on others for injection, less
able to anticipate the time of injection and prepare safely
the necessary equipment. They may also have to inject in
public places or in the homes of other DUs which favor
unsafe practices and the sharing of injection equipment.
However, precarious housing conditions may also be a
consequence of HCV infection [58-60].
The link between HCV infection and crack smoking (in
the last month) can be interpreted in two ways. In France,
most crack users had injected heroine in the 1980s when
no harm reduction policy was in place. Alternatively, shar-
ing of crack pipes has been shown to be a possible way to
transmit HCV [4,61,62]. Glass crack pipes become very
warm and break which result in cuts and lip lesions that
can serve as routes for HCV transmission [63-65]. There-
fore, this association is interesting but complex to inter-
pret. Indeed, it is difficult to say whether the association is
due to crack users injection patterns in the past, whether
it is due to transmission by crack pipes, or whether former
injection drug users, many of whom could be infected by
HCV, have switched to non-injection use of crack to try
and lower their risk of infection with other pathogens.
Although the prevalence of HCV infection was similar by
gender (56% among females vs 61% in males) it does not
imply similar risk factors as shown in our analysis strati-
fied by gender. While our results by gender must be inter-
pretated cautiously because of model unstability (wide
confidence intervals of OR), in a sociological analysis
done within our study, women have been shown to be
highly engaged in at-risk behaviours while consuming
drugs or having sex [49]. Other studies have also reported
differences in risk factors by gender among DUs, with
females being more vulnerable than males [3,66-69].
In our study, questions on drug consumption and at-risk
practices explored the month prior to interview. There-
fore, the impact of long-term consumption and behav-
iours could not be assessed. It would have been useful to
collect drug consumption over entire life to assess drug
consumption trajectory of DUs. We chose not to include
these variables in our questionnaire because the interview
could not last more than 30 minutes in field conditions.
Conclusion
The incidence of HCV infection in the most recent cohort
study of DUs varied from 2% in the Netherlands in 2005
[70] to 10% in France in 2000 [71], 18% in the United
States in 2000–2001 [72] and 42% in London in 2001
[33]. If most of the studies show that harm reduction pol-
icies have not yet had a perceptible impact on HCV trans-
mission among DUs [73], a recent study in the
Netherlands indicates that HCV transmission among DUs
can be reduced by intense and large scale harm reduction
policies combining access to SEP and opiate substitutive
treatments [70,74] and that it takes longer to observe a
measurable impact on HCV than on HIV. In France, it is
too early to document a similar impact since the harm
reduction policy was implemented later than in the Neth-
erlands.
Our study shows that HCV seroprevalence is very high
(59.8%) among DUs in France. The high frequency of
third-party initiation in drug injection, the persistence of
at risk behaviours, the lack of awareness of HCV serosta-
tus, and the extreme social vulnerability facilitate HCV
transmission, particularly for the youngest and most
recent DUs. It is therefore necessary to focus preventionBMC Infectious Diseases 2009, 9:113 http://www.biomedcentral.com/1471-2334/9/113
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strategies on avoiding starting drug injection, sharing of
injection paraphernalia and own reuse, and initiation of
injection for both the initiator and the initiated. Addi-
tional preventive strategies are needed for crack users and
educational programmes for safer injection of injectors. It
is also important to take into account the health of DUs
more globally through integrated social services and to
improve access to screening and treatment of HCV.
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